Karen E Sheppard

19PUBLICATIONS
68CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|May 16, 2025
Sensitivity to immune checkpoint inhibitors in BRAF/MEK inhibitor refractory melanoma.

Riyaben P Patel, Lydia Rui Jia Lim, Reem Saleh

|Feb 01, 2023
Inhibition of the MNK1/2-eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer.

Sathyen A Prabhu, Omar Moussa, Christophe Gonçalves

|Apr 21, 2022
Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?

Emily J Lelliott, Karen E Sheppard, Grant A McArthur

|Mar 02, 2022
Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma.

Lorey K Smith, Tiffany Parmenter, Margarete Kleinschmidt

|Dec 24, 2021
Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma.

Peter Kar Han Lau, Carleen Cullinane, Susan Jackson

|Nov 27, 2021
Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies.

Arwa Alkaraki, Grant A McArthur, Karen E Sheppard

Pageof 4